OLMA OLEMA PHARMACEUTICALS INC Operational Disruptions 8-K Filing 2024 - Clinical Study Results Olema Pharmaceuticals announced interim results from a Phase 1b/2 clinical study of palazestrant in combination with ribociclib for the treatment of metastatic breast cancer.Get access to all SEC 8-K filings of the OLEMA PHARMACEUTICALS INC